Abivax SA (NASDAQ:ABVX) on Monday shared additional Phase 3 maintenance data for investigational ulcerative colitis therapy obefazimod.
Following the announcement, the stock jumped nearly 36%.
Abivax Reports Strong Phase 3 Maintenance Results For Obefazimod The data showed continued clinical benefit in patients who initially failed induction therapy or relapsed during maintenance treatment.
The results also expanded the drug's safety database as the company prepares a planned U.S. regulatory submission later this year.
The newly released topline findings come from ABTECT Maintenance Part 2, a supplemental portion of the company's Phase 3 ulcerative colitis maintenance program.
